Stocks · News reference
Curis gained attention after positive emavusertib data as analyst raised its price target to $43 and highlighted upcoming trial catalysts.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 70.3% to $9.28 during Tuesday's after-market session. The market value of their outstanding shares is at $3.2 million. The company's, Q2 earnings came
Read original at benzingaHC Wainwright & Co. analyst Sara Nik reiterates Curis (NASDAQ:CRIS) with a Buy and maintains $43 price target.
Read original at benzingaGainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release, Q2 earnings
Read original at benzinga